USA: Cancer Research Institute (CRI): CRI’s programs span laboratory research & training, translational investigation, preclinical discovery, & a comprehensive clinical investigation & immunotherapy development strategy.
All of these complementary efforts are necessary for CRI to reach its ultimate goal of bringing more FDA-approved immunotherapies to patients with all types of cancer.
Research Themes:
CLINICAL ACCELERATOR: A powerful program that facilitates collaboration among nonprofits, academic clinicians, and biopharmaceutical companies to speed up refinement of cancer immunotherapies.
2. GRANTS & FELLOWSHIPS
3. CANCER IMMUNOTHERAPY CONSORTIUM: International association of biotech and pharma companies and academic organizations engaged in late-stage cancer immunotherapy development.
